Skip to main content
Erschienen in: DGNeurologie 1/2019

11.01.2019 | Myasthenia gravis | Konsensuspapier

Konsensuspapier zum Einsatz der therapeutischen Apherese in der Neurologie

verfasst von: W. Köhler, C. G. Bien, S. Ehrlich, J. Faiss, C. Finke, R. Gold, A. Günther, L. Harms, F. Heigl, J. Heine, F. Hoffmann, R. W. C. Janzen, G. J. Jungehülsing, B. Kieseier, I. Kleiter, A. Kraft, F. Paul, H. Prüß, S. Schimrigk, C. Sommer, M. Stettner, C. Trebst, H. Tumani

Erschienen in: DGNeurologie | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei einer stetig wachsenden Zahl von neurologischen Erkrankungen spielen Autoimmunität und Autoantikörper eine Rolle. Mit der therapeutischen Apherese (TA) können autoimmunpathogenetisch relevante Bestandteile aus dem Blut des Patienten direkt und rasch entfernt werden. Die TA kommt häufig dann zum Einsatz, wenn in einer akuten Krankheitssituation andere Behandlungen nicht oder nicht ausreichend wirksam waren, wie z. B. beim steroidrefraktären Schub der multiplen Sklerose. Das Einsatzspektrum für die TA reicht bis hin zu lebensbedrohlichen Situationen in der Intensivtherapie. Die Durchführung der Behandlungen erfordert in der Regel eine interdisziplinäre Zusammenarbeit. In diesem Konsensuspapier wird erstmals die bestverfügbare Evidenz für die wichtigsten neurologischen Indikationen unter Einbezug der aktuellen Studienlage und von Hinweisen auf die TA in den Leitlinien der DGN (Deutsche Gesellschaft für Neurologie) zusammengefasst und bewertet, und es werden Handlungsempfehlungen für die klinische Praxis gegeben. Praktische Aspekte der TA wie Therapieschemata, Antikoagulation, Gefäßzugang, Nebenwirkungen und Begleitmedikation sowie das Thema Kostenerstattung werden dargelegt. Die wesentlichen Methoden der TA, der Plasmaaustausch und die Immunadsorption, werden erläutert und ihre Unterschiede erklärt.
Literatur
1.
Zurück zum Zitat Schwartz J, Padmanabhan A, Aui N et al (2016) Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 31:149–162 (Suppl. 163–338)PubMed Schwartz J, Padmanabhan A, Aui N et al (2016) Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 31:149–162 (Suppl. 163–338)PubMed
2.
Zurück zum Zitat Boser M, Kielstein J (2016) Plasmaaustausch – „It’s time for a change in plasma exchange“. Dial Aktuell 20(10):497–500 Boser M, Kielstein J (2016) Plasmaaustausch – „It’s time for a change in plasma exchange“. Dial Aktuell 20(10):497–500
3.
Zurück zum Zitat Köhler W, Bucka C, Klingel R (2011) A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 26:347–355PubMed Köhler W, Bucka C, Klingel R (2011) A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 26:347–355PubMed
4.
Zurück zum Zitat Heigl F, Hettich R, Arendt R et al (2013) Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients. Atheroscler Suppl 14:167–173PubMed Heigl F, Hettich R, Arendt R et al (2013) Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients. Atheroscler Suppl 14:167–173PubMed
5.
Zurück zum Zitat Heigl F, Hettich R (2015) Behandlung der steroidrefraktären Multiplen Sklerose. Einsatzgebiet der therapeutischen Apherese. Dial Aktuell 19(4):198–206 Heigl F, Hettich R (2015) Behandlung der steroidrefraktären Multiplen Sklerose. Einsatzgebiet der therapeutischen Apherese. Dial Aktuell 19(4):198–206
7.
Zurück zum Zitat Koessler J, Kobsar A, Kuhn S et al (2015) The effect of immunoadsorption with the immusorba TR-350 on coagulation compared to plasma exchange. Vox Sang 108:46–21PubMed Koessler J, Kobsar A, Kuhn S et al (2015) The effect of immunoadsorption with the immusorba TR-350 on coagulation compared to plasma exchange. Vox Sang 108:46–21PubMed
8.
Zurück zum Zitat Cheng C, Hendrickson J, Tormey C, Sidu D (2017) Therapeutic plasma exchange and its impact on drug levels. An ACLPS critical review. Am J Clin Pathol 148:190–198PubMed Cheng C, Hendrickson J, Tormey C, Sidu D (2017) Therapeutic plasma exchange and its impact on drug levels. An ACLPS critical review. Am J Clin Pathol 148:190–198PubMed
10.
Zurück zum Zitat McGuckin S, Westwood J, Webster H et al (2014) Characteriszation of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience. Vox Sang 106:116–166 McGuckin S, Westwood J, Webster H et al (2014) Characteriszation of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience. Vox Sang 106:116–166
11.
Zurück zum Zitat Álvarez M, Luis-Hidalgo M, Bracho MA et al (2016) Transmission of human immunodeficiency virus type-1 by freshfrozen plasma treated with methylene blue and light. Transfusion 56(4):831–836PubMed Álvarez M, Luis-Hidalgo M, Bracho MA et al (2016) Transmission of human immunodeficiency virus type-1 by freshfrozen plasma treated with methylene blue and light. Transfusion 56(4):831–836PubMed
12.
Zurück zum Zitat Hauser L, Roque-Afonso AM, Beylouné A et al (2014) Hepatitis E transmission by transfusion of intercept blood systemtreated plasma. Blood 123:796–797PubMed Hauser L, Roque-Afonso AM, Beylouné A et al (2014) Hepatitis E transmission by transfusion of intercept blood systemtreated plasma. Blood 123:796–797PubMed
13.
Zurück zum Zitat Hewitt P, Ijaz S, Brailsford S et al (2014) Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 384:1766–1773PubMed Hewitt P, Ijaz S, Brailsford S et al (2014) Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 384:1766–1773PubMed
14.
Zurück zum Zitat Zöllner S, Pablik E, Druml W et al (2014) Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two. Blood Purif 38:160–166PubMed Zöllner S, Pablik E, Druml W et al (2014) Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two. Blood Purif 38:160–166PubMed
15.
Zurück zum Zitat Schneider-Gold C, Krenzer M, Klinker E et al (2016) Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration. Ther Adv Neurol Disord 9(4):297–303PubMedPubMedCentral Schneider-Gold C, Krenzer M, Klinker E et al (2016) Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration. Ther Adv Neurol Disord 9(4):297–303PubMedPubMedCentral
16.
Zurück zum Zitat Klingel R, Heibges A, Fassbender C (2009) Plasma exchange and immunoadsorption for autoimmune neurologic disorders – current guidelines and future perspectives. Atheroscler Suppl 10(5):129–132PubMed Klingel R, Heibges A, Fassbender C (2009) Plasma exchange and immunoadsorption for autoimmune neurologic disorders – current guidelines and future perspectives. Atheroscler Suppl 10(5):129–132PubMed
17.
Zurück zum Zitat Grob D, Simpson D, Mitsumoto H et al (1995) Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 45:338–344PubMed Grob D, Simpson D, Mitsumoto H et al (1995) Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 45:338–344PubMed
18.
Zurück zum Zitat Fassbender C, Heibges A (2013) Therapeutische Apherese – Kostenerstattung in Deutschland. Dial Aktuell 17(10):531–534 Fassbender C, Heibges A (2013) Therapeutische Apherese – Kostenerstattung in Deutschland. Dial Aktuell 17(10):531–534
20.
Zurück zum Zitat Kribben A, Lütkes P, Müller H (2004) Kostenkalkulation für die Dialyse und andere Therapieverfahren in der Nephrologie. Krankenhaus 5:356–363 Kribben A, Lütkes P, Müller H (2004) Kostenkalkulation für die Dialyse und andere Therapieverfahren in der Nephrologie. Krankenhaus 5:356–363
21.
Zurück zum Zitat Petersen G, Wittmann R, Arndt V et al (2014) Epidemiologie der Multiplen Sklerose in Deutschland. Nervenarzt 85(8):990–998PubMed Petersen G, Wittmann R, Arndt V et al (2014) Epidemiologie der Multiplen Sklerose in Deutschland. Nervenarzt 85(8):990–998PubMed
23.
Zurück zum Zitat Novotna M, Solán M, Zeid N et al (2015) Poorly relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology 85(8):722–729PubMedPubMedCentral Novotna M, Solán M, Zeid N et al (2015) Poorly relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology 85(8):722–729PubMedPubMedCentral
24.
Zurück zum Zitat Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med 354:942–955PubMed Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med 354:942–955PubMed
25.
Zurück zum Zitat Meinl E, Derfuss T, Krumbholz M, Pröbstel AK, Hohlfeld R (2011) Humoral autoimmunity in multiple sclerosis. J Neurol Sci 306:180–182PubMed Meinl E, Derfuss T, Krumbholz M, Pröbstel AK, Hohlfeld R (2011) Humoral autoimmunity in multiple sclerosis. J Neurol Sci 306:180–182PubMed
26.
Zurück zum Zitat Hemmer B, Kerschensteiner M, Korn T (2015) Role of the innate and adaptive immune response in the course of multiple sclerosis. Lancet Neurol 14:406–419PubMed Hemmer B, Kerschensteiner M, Korn T (2015) Role of the innate and adaptive immune response in the course of multiple sclerosis. Lancet Neurol 14:406–419PubMed
27.
Zurück zum Zitat Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demylination. Ann Neurol 47:707–717PubMed Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demylination. Ann Neurol 47:707–717PubMed
28.
Zurück zum Zitat Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A et al (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366(9485):579–582PubMed Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A et al (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366(9485):579–582PubMed
29.
Zurück zum Zitat Stork L, Ellenberger D, Beißbarth T, Friede T, Lucchinetti CL, Brück W, Metz I (2018) Differences in the response to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis. JAMA Neurol 75(4):428–435PubMedPubMedCentral Stork L, Ellenberger D, Beißbarth T, Friede T, Lucchinetti CL, Brück W, Metz I (2018) Differences in the response to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis. JAMA Neurol 75(4):428–435PubMedPubMedCentral
30.
Zurück zum Zitat Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, LangerGould A, Smith CH, HERMES Trial Group (2008) B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688PubMed Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, LangerGould A, Smith CH, HERMES Trial Group (2008) B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688PubMed
31.
Zurück zum Zitat Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, OPERA I and OPERA II Clinical Investigators (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234PubMed Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, OPERA I and OPERA II Clinical Investigators (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234PubMed
32.
Zurück zum Zitat Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS, ORATORIO Clinical Investigators (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209–220PubMed Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS, ORATORIO Clinical Investigators (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209–220PubMed
33.
Zurück zum Zitat Klingel R, Heibges A, Fassbender C (2013) Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies – perspectives for immunoadsorption. Atheroscler Suppl 14:161–165PubMed Klingel R, Heibges A, Fassbender C (2013) Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies – perspectives for immunoadsorption. Atheroscler Suppl 14:161–165PubMed
35.
Zurück zum Zitat Schilling S, Linker R, König F et al (2006) Plasmaaustausch bei steroidresistenten Multiple Sklerose Schüben – Klinische Erfahrungen an 16 Patienten. Nervenarzt 77:430–438PubMed Schilling S, Linker R, König F et al (2006) Plasmaaustausch bei steroidresistenten Multiple Sklerose Schüben – Klinische Erfahrungen an 16 Patienten. Nervenarzt 77:430–438PubMed
36.
Zurück zum Zitat Schröder A, Fischer M, Meyer C et al (2009) Plasmapherese in der Eskalationstherapie der Multiplen Sklerose: Verlaufsbeobachtung an 35 Patienten. Aktuelle Neurol 36:105–110 Schröder A, Fischer M, Meyer C et al (2009) Plasmapherese in der Eskalationstherapie der Multiplen Sklerose: Verlaufsbeobachtung an 35 Patienten. Aktuelle Neurol 36:105–110
37.
Zurück zum Zitat Trebst C, Reising A, Kielstein J et al (2009) Plasma exchange therapy in steroid unresponsive relapses in patients with multiple sclerosis. Blood Purif 28:108–115PubMed Trebst C, Reising A, Kielstein J et al (2009) Plasma exchange therapy in steroid unresponsive relapses in patients with multiple sclerosis. Blood Purif 28:108–115PubMed
38.
Zurück zum Zitat Weinshenker BG, O’Brien PC, Petterson TM et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886PubMed Weinshenker BG, O’Brien PC, Petterson TM et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886PubMed
39.
Zurück zum Zitat Hoffmann F, Kraft A, Heigl F et al (2015) Tryptophan-Immunadsorption bei Multipler Sklerose und Neuromyelitis optica. Therapieoption bei akuten Schüben in der Schwangerschaft und Stillphase. Nervenarzt 86:179–186PubMed Hoffmann F, Kraft A, Heigl F et al (2015) Tryptophan-Immunadsorption bei Multipler Sklerose und Neuromyelitis optica. Therapieoption bei akuten Schüben in der Schwangerschaft und Stillphase. Nervenarzt 86:179–186PubMed
40.
Zurück zum Zitat Koziolek M, Tampe D, Bähr M et al (2012) Immunoadsorption therapy in patients with multiple sclerosis with steroidrefractory optical neuritis. J Neuroinflammation 9:80PubMedPubMedCentral Koziolek M, Tampe D, Bähr M et al (2012) Immunoadsorption therapy in patients with multiple sclerosis with steroidrefractory optical neuritis. J Neuroinflammation 9:80PubMedPubMedCentral
41.
Zurück zum Zitat Mauch E, Zwanzger J, Hettich R et al (2011) Immunadsorption bei steroidrefraktärem Schub der Multiplen Sklerose. Nervenarzt 82:1590–1595PubMed Mauch E, Zwanzger J, Hettich R et al (2011) Immunadsorption bei steroidrefraktärem Schub der Multiplen Sklerose. Nervenarzt 82:1590–1595PubMed
42.
Zurück zum Zitat Schimrigk S, Adibi I, Eberl A et al (2012) Immunadsorption zur Eskalation der Schubtherapie bei MS. Aktuelle Neurol 39:174–179 Schimrigk S, Adibi I, Eberl A et al (2012) Immunadsorption zur Eskalation der Schubtherapie bei MS. Aktuelle Neurol 39:174–179
43.
Zurück zum Zitat Schimrigk S, Faiss J, Köhler W et al (2016) Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoadsorption – observational multicenter study with 147 patients. Eur Neurol 75:300–306PubMed Schimrigk S, Faiss J, Köhler W et al (2016) Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoadsorption – observational multicenter study with 147 patients. Eur Neurol 75:300–306PubMed
44.
Zurück zum Zitat Trebst C, Bronzlik P, Kielstein J et al (2012) Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 33:1–6PubMed Trebst C, Bronzlik P, Kielstein J et al (2012) Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 33:1–6PubMed
45.
Zurück zum Zitat De Masi R, Accoto S, Orlando S et al (2015) Dramatic recovery of steroid-refractory relapsed multiple sclerosis following fingolimod discontinuation using selective immune adsorption. BMC Neurol 15:125PubMedPubMedCentral De Masi R, Accoto S, Orlando S et al (2015) Dramatic recovery of steroid-refractory relapsed multiple sclerosis following fingolimod discontinuation using selective immune adsorption. BMC Neurol 15:125PubMedPubMedCentral
46.
Zurück zum Zitat Dorst J, Kunz M, Vintonyak O, Senel M, Rau D, Fathinia P, Hansel A, Endruhn S, Fangerau T, Taranu D, Gastl R, Jesse S, Schuster J, Ludolph AC, Tumani H (2016) Immunoadsorption with regenerating columns in treatment of steroid refractory relapse in multiple sclerosis and optic neuritis. J Mult Scler (Foster City) 3:2. https://doi.org/10.4172/2376-0389.1000178 CrossRef Dorst J, Kunz M, Vintonyak O, Senel M, Rau D, Fathinia P, Hansel A, Endruhn S, Fangerau T, Taranu D, Gastl R, Jesse S, Schuster J, Ludolph AC, Tumani H (2016) Immunoadsorption with regenerating columns in treatment of steroid refractory relapse in multiple sclerosis and optic neuritis. J Mult Scler (Foster City) 3:2. https://​doi.​org/​10.​4172/​2376-0389.​1000178 CrossRef
48.
Zurück zum Zitat Sutton D, Nair R, Rock G et al (1989) Complications of plasma exchange. Transfusion 29(2):121–127 Sutton D, Nair R, Rock G et al (1989) Complications of plasma exchange. Transfusion 29(2):121–127
49.
Zurück zum Zitat Hellwig K, Haghikia A, Rockhoff M et al (2012) Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 5(5):247–253PubMedPubMedCentral Hellwig K, Haghikia A, Rockhoff M et al (2012) Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 5(5):247–253PubMedPubMedCentral
50.
Zurück zum Zitat Park-Wyllie L, Mazzotta P, Pastuszak A et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidermiological studies. Teratology 62(6):385–392PubMed Park-Wyllie L, Mazzotta P, Pastuszak A et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidermiological studies. Teratology 62(6):385–392PubMed
52.
Zurück zum Zitat Gur C, Diav-Citrin O, Shechtman S et al (2004) Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 18(1):93–101PubMed Gur C, Diav-Citrin O, Shechtman S et al (2004) Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 18(1):93–101PubMed
53.
Zurück zum Zitat Hoffmann F, Kraft A, Heigl F et al (2018) Tryptophan immunoadsorption during pregnancy and breatsfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. Ther Adv Neurol Disord 11:1–12 Hoffmann F, Kraft A, Heigl F et al (2018) Tryptophan immunoadsorption during pregnancy and breatsfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. Ther Adv Neurol Disord 11:1–12
54.
Zurück zum Zitat Marson P, Gervasi MT, Tison T et al (2015) Therapeutic apheresis in pregnancy: general considerations and current practice. Transfus Apher Sci 53:256–261PubMed Marson P, Gervasi MT, Tison T et al (2015) Therapeutic apheresis in pregnancy: general considerations and current practice. Transfus Apher Sci 53:256–261PubMed
56.
Zurück zum Zitat Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B (2014) Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol 13(9):936–948PubMedPubMedCentral Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B (2014) Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol 13(9):936–948PubMedPubMedCentral
58.
Zurück zum Zitat Koziolek M, Mühlhausen J, Friede T et al (2013) Therapeutic apheresis in pediatric patients with acute CNS inflammatory demyelinating disease. Blood Purif 36:92–97PubMed Koziolek M, Mühlhausen J, Friede T et al (2013) Therapeutic apheresis in pediatric patients with acute CNS inflammatory demyelinating disease. Blood Purif 36:92–97PubMed
59.
Zurück zum Zitat Paglialonga F, Schmitt C, Shroff R et al (2015) Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units. Pediatr Nephrol 30(1):103–111PubMed Paglialonga F, Schmitt C, Shroff R et al (2015) Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units. Pediatr Nephrol 30(1):103–111PubMed
60.
Zurück zum Zitat Clifford DB, De Luca A, Simpson DM et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 4:438–446 Clifford DB, De Luca A, Simpson DM et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 4:438–446
61.
Zurück zum Zitat Wenning W, Haghikia A, Laubenberger J et al (2009) Treatment of progressive mulitfocal leukoencephalopathy assoziated with natalizumab. N Engl J Med 361(11):1075–1108PubMed Wenning W, Haghikia A, Laubenberger J et al (2009) Treatment of progressive mulitfocal leukoencephalopathy assoziated with natalizumab. N Engl J Med 361(11):1075–1108PubMed
62.
Zurück zum Zitat Landi D, Rossi N, Zagalia S et al (2017) No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88:1144–1152PubMed Landi D, Rossi N, Zagalia S et al (2017) No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88:1144–1152PubMed
63.
Zurück zum Zitat Pitarokoili K, Gold R (2018) Ziel der PML-Behandlung: die immunologische Balance erhalten. Kommentar. Info Neurol Psychiatr 20(1):18 Pitarokoili K, Gold R (2018) Ziel der PML-Behandlung: die immunologische Balance erhalten. Kommentar. Info Neurol Psychiatr 20(1):18
64.
Zurück zum Zitat Jarius S, Wildemann B, Paul F (2014) Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 176:149–164PubMedPubMedCentral Jarius S, Wildemann B, Paul F (2014) Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 176:149–164PubMedPubMedCentral
65.
Zurück zum Zitat Kremer L, Mealy M, Jacob A et al (2014) Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 20:843–847PubMed Kremer L, Mealy M, Jacob A et al (2014) Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 20:843–847PubMed
66.
Zurück zum Zitat Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112PubMed Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112PubMed
67.
Zurück zum Zitat Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6:383–392PubMed Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6:383–392PubMed
69.
Zurück zum Zitat Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189PubMedPubMedCentral Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189PubMedPubMedCentral
70.
Zurück zum Zitat Mader S, Gredler V, Schanda K et al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:184PubMedPubMedCentral Mader S, Gredler V, Schanda K et al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:184PubMedPubMedCentral
71.
Zurück zum Zitat Zamvil SS, Slavin AJ (2015) Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2:e62PubMedPubMedCentral Zamvil SS, Slavin AJ (2015) Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2:e62PubMedPubMedCentral
72.
Zurück zum Zitat Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15(1):134PubMedPubMedCentral Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15(1):134PubMedPubMedCentral
73.
Zurück zum Zitat Sellner J, Boggild M, Clanet M et al (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17:1019–1032PubMed Sellner J, Boggild M, Clanet M et al (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17:1019–1032PubMed
75.
Zurück zum Zitat Trebst C, Jarius S, Berthele A et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261:1–16PubMed Trebst C, Jarius S, Berthele A et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261:1–16PubMed
77.
Zurück zum Zitat Takeshita Y, Obermeier B, Cotleur AC et al (2016) Effects of neuromyelitis optica-IgG at the blood brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 4(1):e311PubMedPubMedCentral Takeshita Y, Obermeier B, Cotleur AC et al (2016) Effects of neuromyelitis optica-IgG at the blood brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 4(1):e311PubMedPubMedCentral
78.
Zurück zum Zitat Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14PubMedPubMedCentral Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14PubMedPubMedCentral
79.
Zurück zum Zitat Kleiter I, Gold R (2016) Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 13:70–83PubMed Kleiter I, Gold R (2016) Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 13:70–83PubMed
80.
Zurück zum Zitat Aguilera AJ, Carlow TJ, Smith KJ, Simon TL (1985) Lymphocytaplasmapheresis in Devic’s syndrome. Transfusion 25:5456 Aguilera AJ, Carlow TJ, Smith KJ, Simon TL (1985) Lymphocytaplasmapheresis in Devic’s syndrome. Transfusion 25:5456
81.
Zurück zum Zitat Konttinen YT, Kinnunen E, von Bonsdorff M et al (1987) Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjogren’s syndrome. Arthritis Rheum 30:339–344PubMed Konttinen YT, Kinnunen E, von Bonsdorff M et al (1987) Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjogren’s syndrome. Arthritis Rheum 30:339–344PubMed
82.
Zurück zum Zitat Watanabe S, Nakashima I, Misu T et al (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13:128–132PubMed Watanabe S, Nakashima I, Misu T et al (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13:128–132PubMed
83.
Zurück zum Zitat Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P (2009) Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 15:487–492PubMed Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P (2009) Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 15:487–492PubMed
84.
Zurück zum Zitat Merle H, Olindo S, Jeannin S et al (2012) Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 130:858–862PubMed Merle H, Olindo S, Jeannin S et al (2012) Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 130:858–862PubMed
85.
Zurück zum Zitat Magana SM, Keegan BM, Weinshenker BG et al (2011) Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 68:870–878PubMedPubMedCentral Magana SM, Keegan BM, Weinshenker BG et al (2011) Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 68:870–878PubMedPubMedCentral
86.
Zurück zum Zitat Lim YM, Pyun SY, Kang BH, Kim J, Kim KK (2013) Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler 19:1216–1218PubMed Lim YM, Pyun SY, Kang BH, Kim J, Kim KK (2013) Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler 19:1216–1218PubMed
87.
Zurück zum Zitat Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M (2016) Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 22:185–192PubMed Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M (2016) Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 22:185–192PubMed
88.
Zurück zum Zitat Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ (2013) Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol 9:3642 Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ (2013) Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol 9:3642
89.
Zurück zum Zitat Deschamps R, Gueguen A, Parquet N et al (2016) Plasma exchange response in 34 patients with severe optic neuritis. J Neurol 263:883–887PubMed Deschamps R, Gueguen A, Parquet N et al (2016) Plasma exchange response in 34 patients with severe optic neuritis. J Neurol 263:883–887PubMed
90.
Zurück zum Zitat Kleiter I, Gahlen A, Borisow N et al (2016) Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol 79:206–216PubMed Kleiter I, Gahlen A, Borisow N et al (2016) Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol 79:206–216PubMed
91.
Zurück zum Zitat Llufriu S, Castillo J, Blanco Y et al (2009) Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology 73:949–953PubMed Llufriu S, Castillo J, Blanco Y et al (2009) Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology 73:949–953PubMed
92.
Zurück zum Zitat Bonnan M, Valentino R, Debeugny S et al (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89:346–351PubMed Bonnan M, Valentino R, Debeugny S et al (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89:346–351PubMed
93.
Zurück zum Zitat Jurewicz A, Selmaj K (2015) Relapse of neuromyelitis optica during pregnancy – treatment options and literature review. Clin Neurol Neurosurg 130:159–161PubMed Jurewicz A, Selmaj K (2015) Relapse of neuromyelitis optica during pregnancy – treatment options and literature review. Clin Neurol Neurosurg 130:159–161PubMed
94.
Zurück zum Zitat Rubio Tabares J, Amaya Gonzalez PF (2016) Plasma exchange therapy for a severe relapse of Devic’s disease in a pregnant woman: a case report and concise review. Clin Neurol Neurosurg 148:88–90PubMed Rubio Tabares J, Amaya Gonzalez PF (2016) Plasma exchange therapy for a severe relapse of Devic’s disease in a pregnant woman: a case report and concise review. Clin Neurol Neurosurg 148:88–90PubMed
95.
Zurück zum Zitat Kobayashi M, Nanri K, Taguchi T et al (2015) Immunoadsorption therapy for neuromyelitis optica spectrum disorders long after the acute phase. J Clin Apher 30:43–45PubMed Kobayashi M, Nanri K, Taguchi T et al (2015) Immunoadsorption therapy for neuromyelitis optica spectrum disorders long after the acute phase. J Clin Apher 30:43–45PubMed
96.
Zurück zum Zitat Faissner S, Nikolayczik J, Chan A et al (2016) Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord 9(4):281–286PubMedPubMedCentral Faissner S, Nikolayczik J, Chan A et al (2016) Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord 9(4):281–286PubMedPubMedCentral
97.
Zurück zum Zitat Yasuda T, Mikami T, Kawase Y (2015) Efficacy of tryptophan immunoadsorption plasmapheresis for neuromyelitis optica in two cases. Ther Apher Dial 19:411–412PubMed Yasuda T, Mikami T, Kawase Y (2015) Efficacy of tryptophan immunoadsorption plasmapheresis for neuromyelitis optica in two cases. Ther Apher Dial 19:411–412PubMed
98.
Zurück zum Zitat Mauch E, Zwanzger J, Hettich R, Fassbender C, Klingel R, Heigl F (2011) Immunoadsorption for steroid-unresponsive multiple sclerosis-relapses: clinical data of 14 patients. Nervenarzt 82:1590–1595PubMed Mauch E, Zwanzger J, Hettich R, Fassbender C, Klingel R, Heigl F (2011) Immunoadsorption for steroid-unresponsive multiple sclerosis-relapses: clinical data of 14 patients. Nervenarzt 82:1590–1595PubMed
99.
Zurück zum Zitat Kohsaka M, Tanaka M, Tahara M, Araki Y, Mori S, Konishi T (2010) A case of subacute myelitis with anti-aquaporin 4 antibody after thymectomy for myasthenia gravis: review of autoimmune diseases after thymectomy. Rinsho Shinkeigaku 50:111–113PubMed Kohsaka M, Tanaka M, Tahara M, Araki Y, Mori S, Konishi T (2010) A case of subacute myelitis with anti-aquaporin 4 antibody after thymectomy for myasthenia gravis: review of autoimmune diseases after thymectomy. Rinsho Shinkeigaku 50:111–113PubMed
100.
Zurück zum Zitat Arai M (2009) Relapsing transverse myelitis with anti-aquaporin 4 seropositivity: possible beneficial effects of ciclosporin. Rinsho Shinkeigaku 49:48–51PubMed Arai M (2009) Relapsing transverse myelitis with anti-aquaporin 4 seropositivity: possible beneficial effects of ciclosporin. Rinsho Shinkeigaku 49:48–51PubMed
101.
Zurück zum Zitat Miyamoto K, Kusunoki S (2009) Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 13:505–508PubMed Miyamoto K, Kusunoki S (2009) Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 13:505–508PubMed
102.
Zurück zum Zitat Khatri BO, Kramer J, Dukic M, Palencia M, Verre W (2012) Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apher 27:183–192PubMed Khatri BO, Kramer J, Dukic M, Palencia M, Verre W (2012) Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apher 27:183–192PubMed
104.
Zurück zum Zitat Graus F et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391–404PubMedPubMedCentral Graus F et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391–404PubMedPubMedCentral
105.
Zurück zum Zitat Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C (2015) Imaging of autoimmune encephalitis – relevance for clinical practice and hippocampal function. Neuroscience 309:68–83PubMed Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C (2015) Imaging of autoimmune encephalitis – relevance for clinical practice and hippocampal function. Neuroscience 309:68–83PubMed
106.
Zurück zum Zitat Dalmau J et al (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098PubMedPubMedCentral Dalmau J et al (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098PubMedPubMedCentral
107.
Zurück zum Zitat Titulaer MJ et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165PubMedPubMedCentral Titulaer MJ et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165PubMedPubMedCentral
109.
Zurück zum Zitat Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10(1):63–74PubMedPubMedCentral Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10(1):63–74PubMedPubMedCentral
110.
Zurück zum Zitat Heine J et al (2016) Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study. J Neurol 263(12):2395–2402PubMed Heine J et al (2016) Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study. J Neurol 263(12):2395–2402PubMed
111.
Zurück zum Zitat Dogan Onugoren M et al (2016) Immunoadsorption therapy in autoimmune encephalitides. Neurol Neuroimmunol Neuroinflamm 3(2):e207–e207PubMedPubMedCentral Dogan Onugoren M et al (2016) Immunoadsorption therapy in autoimmune encephalitides. Neurol Neuroimmunol Neuroinflamm 3(2):e207–e207PubMedPubMedCentral
112.
Zurück zum Zitat DeSena AD et al (2015) Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-nmethyl-d-aspartate receptor antibody encephalitis: a retrospective review. J Clin Apher 30(4):212–216PubMed DeSena AD et al (2015) Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-nmethyl-d-aspartate receptor antibody encephalitis: a retrospective review. J Clin Apher 30(4):212–216PubMed
113.
Zurück zum Zitat Pham HP, Daniel-Johnson JA, Stotler BA, Stephens H, Schwartz J (2011) Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis. J Clin Apher 26(6):320–325PubMed Pham HP, Daniel-Johnson JA, Stotler BA, Stephens H, Schwartz J (2011) Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis. J Clin Apher 26(6):320–325PubMed
114.
Zurück zum Zitat Köhler W et al (2014) Tryptophan immunoadsorption for the treatment of autoimmune encephalitis. Eur J Neurol 22:203–206PubMed Köhler W et al (2014) Tryptophan immunoadsorption for the treatment of autoimmune encephalitis. Eur J Neurol 22:203–206PubMed
115.
Zurück zum Zitat Mazzi G, De Roia D, Cruciatti B, Matà S, Catapano R (2008) Plasma exchange for anti GAD associated non paraneoplastic limbic encephalitis. Transfus Apher Sci 39(3):229–233PubMed Mazzi G, De Roia D, Cruciatti B, Matà S, Catapano R (2008) Plasma exchange for anti GAD associated non paraneoplastic limbic encephalitis. Transfus Apher Sci 39(3):229–233PubMed
116.
Zurück zum Zitat Ariño H et al (2014) Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol 71(8):1009–1016PubMedPubMedCentral Ariño H et al (2014) Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol 71(8):1009–1016PubMedPubMedCentral
117.
Zurück zum Zitat Smith JH (2011) N‑methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus. Arch Neurol 68(8):1069PubMed Smith JH (2011) N‑methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus. Arch Neurol 68(8):1069PubMed
118.
Zurück zum Zitat Ehrlich S et al (2012) Therapeutische Apherese bei autoimmuner Enzephalitis. Nervenarzt 84(4):498–507 Ehrlich S et al (2012) Therapeutische Apherese bei autoimmuner Enzephalitis. Nervenarzt 84(4):498–507
119.
Zurück zum Zitat Chan SHS, Wong VCN, Fung C, Dale RC, Vincent A (2010) Anti-NMDA receptor encephalitis with atypical brain changes on MRI. Pediatr Neurol 43(4):274–278PubMed Chan SHS, Wong VCN, Fung C, Dale RC, Vincent A (2010) Anti-NMDA receptor encephalitis with atypical brain changes on MRI. Pediatr Neurol 43(4):274–278PubMed
120.
Zurück zum Zitat Vincent A et al (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127(Pt 3):701–712PubMed Vincent A et al (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127(Pt 3):701–712PubMed
121.
Zurück zum Zitat Jaben EA, Winters JL (2012) Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels: a report of five cases and review of the literature. J Clin Apher 27(5):267–273PubMed Jaben EA, Winters JL (2012) Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels: a report of five cases and review of the literature. J Clin Apher 27(5):267–273PubMed
122.
Zurück zum Zitat Martin IW, Martin C‑LB, Dunbar NM, Lee SL, Szczepiorkowski ZM (2016) Therapeutic plasma exchange as a steroid-sparing therapy in a patient with limbic encephalitis due to antibodies to voltage-gated potassium channels. J Clin Apher 31(1):63–65PubMed Martin IW, Martin C‑LB, Dunbar NM, Lee SL, Szczepiorkowski ZM (2016) Therapeutic plasma exchange as a steroid-sparing therapy in a patient with limbic encephalitis due to antibodies to voltage-gated potassium channels. J Clin Apher 31(1):63–65PubMed
125.
Zurück zum Zitat Rickman OB, Parisi JE, Yu Z, Lennon VA, Vernino S (2000) Fulminant autoimmune cortical encephalitis associated with thymoma treated with plasma exchange. Mayo Clin Proc 75(12):1321–1326PubMed Rickman OB, Parisi JE, Yu Z, Lennon VA, Vernino S (2000) Fulminant autoimmune cortical encephalitis associated with thymoma treated with plasma exchange. Mayo Clin Proc 75(12):1321–1326PubMed
126.
Zurück zum Zitat Batchelor TT, Platten M, Hochberg FH (1998) Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol 40(2):131–136PubMed Batchelor TT, Platten M, Hochberg FH (1998) Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol 40(2):131–136PubMed
127.
Zurück zum Zitat Mori M, Kuwabara S, Yoshiyama M, Kanesaka T, Ogata T, Hattori T (2002) Successful immune treatment for nonparaneoplastic limbic encephalitis. J Neurol Sci 201(1–2):85–88PubMed Mori M, Kuwabara S, Yoshiyama M, Kanesaka T, Ogata T, Hattori T (2002) Successful immune treatment for nonparaneoplastic limbic encephalitis. J Neurol Sci 201(1–2):85–88PubMed
128.
Zurück zum Zitat Pevzner A, Schoser B, Peters K et al (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259:427–435PubMed Pevzner A, Schoser B, Peters K et al (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259:427–435PubMed
129.
Zurück zum Zitat Gasperi C, Melms A, Schoser B et al (2014) Anti-agrin autoantibodies in myasthenia gravis. Neurology 82:1976–1983PubMed Gasperi C, Melms A, Schoser B et al (2014) Anti-agrin autoantibodies in myasthenia gravis. Neurology 82:1976–1983PubMed
130.
Zurück zum Zitat Otsuka K, Ito M, Ohkawara B et al (2015) Collagen Q and anti-MuSK autoantibodies competitively suppress agrin/LRP4/MuSK signaling. Sci Rep 5:1392 Otsuka K, Ito M, Ohkawara B et al (2015) Collagen Q and anti-MuSK autoantibodies competitively suppress agrin/LRP4/MuSK signaling. Sci Rep 5:1392
131.
Zurück zum Zitat Cortes-Vicente E, Gallardo E, Martinez MA et al (2016) Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol 73:1099–1104PubMed Cortes-Vicente E, Gallardo E, Martinez MA et al (2016) Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol 73:1099–1104PubMed
132.
Zurück zum Zitat Gilhus NE, Verschuur JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023–1036PubMed Gilhus NE, Verschuur JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023–1036PubMed
134.
Zurück zum Zitat Wiendl H (2012) Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndroms. In: Diener, Weimar (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, New York (Zuletzt überprüft am: 20.03.2018; (Zugriff am 21.08.2018) URL:http://www.dgn.org/) Wiendl H (2012) Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndroms. In: Diener, Weimar (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, New York (Zuletzt überprüft am: 20.03.2018; (Zugriff am 21.08.2018) URL:http://​www.​dgn.​org/​)
135.
Zurück zum Zitat Haas M, Mayr N, Zeitlhofer J et al (2002) Long-term treatment of myasthenia greavis with immunoadsorption. J Clin Apher 17:84–87PubMed Haas M, Mayr N, Zeitlhofer J et al (2002) Long-term treatment of myasthenia greavis with immunoadsorption. J Clin Apher 17:84–87PubMed
136.
Zurück zum Zitat Klehmet J, Ohlraun S, Meisel A (2014) Myasthenia gravis und Schwangerschaft. Aktuelle Neurol 41:447–453 Klehmet J, Ohlraun S, Meisel A (2014) Myasthenia gravis und Schwangerschaft. Aktuelle Neurol 41:447–453
137.
Zurück zum Zitat Wagner S, Janzen RW, Mohs C et al (2008) Langzeitbehandlung der therapierefraktären Myasthenia gravis mittels Immunadsorption. Dtsch Med Wochenschr 133:2377–2382PubMed Wagner S, Janzen RW, Mohs C et al (2008) Langzeitbehandlung der therapierefraktären Myasthenia gravis mittels Immunadsorption. Dtsch Med Wochenschr 133:2377–2382PubMed
138.
Zurück zum Zitat Barth D, Nouri MN, Ng E et al (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23):2017–2023PubMedPubMedCentral Barth D, Nouri MN, Ng E et al (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23):2017–2023PubMedPubMedCentral
139.
Zurück zum Zitat Yamada C, Pham HP, Wu Y et al (2017) Report of the ASFA apheresis registry on muscle specific kinase antibody positive myasthenia gravis. J Clin Apher 32(1):5–11PubMed Yamada C, Pham HP, Wu Y et al (2017) Report of the ASFA apheresis registry on muscle specific kinase antibody positive myasthenia gravis. J Clin Apher 32(1):5–11PubMed
140.
Zurück zum Zitat Antozzi C (2013) Immunoadsorption in patients with autoimmune ion channel disorders of the peripheral nervous system. Atheroscler Suppl 14:219–222PubMed Antozzi C (2013) Immunoadsorption in patients with autoimmune ion channel disorders of the peripheral nervous system. Atheroscler Suppl 14:219–222PubMed
141.
Zurück zum Zitat Sauter M, Bender A, Heller F, Sitter T (2010) A case report of the efficient reduction of calcium channel antibodies by tryptophan ligand immunoadsorption in a patient with Lambert-Eaton syndrome. Ther Apher Dial 14:364–367PubMed Sauter M, Bender A, Heller F, Sitter T (2010) A case report of the efficient reduction of calcium channel antibodies by tryptophan ligand immunoadsorption in a patient with Lambert-Eaton syndrome. Ther Apher Dial 14:364–367PubMed
142.
Zurück zum Zitat Toyka K, Drachman D, Griffin D et al (1977) Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 296:125–131PubMed Toyka K, Drachman D, Griffin D et al (1977) Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 296:125–131PubMed
143.
Zurück zum Zitat Henze T, Janzen RW, Schumm F et al (2010) Immuntherapie bei Myasthenia gravis und Lambert-Eaton-Syndrom. Teil 2: Intravenöse Immunglobuline und Plasmaaustauschverfahren. Aktuelle Neurol 37:518–523 Henze T, Janzen RW, Schumm F et al (2010) Immuntherapie bei Myasthenia gravis und Lambert-Eaton-Syndrom. Teil 2: Intravenöse Immunglobuline und Plasmaaustauschverfahren. Aktuelle Neurol 37:518–523
144.
Zurück zum Zitat Skeie GO, Apostolski S, Evoli A et al (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893–902PubMed Skeie GO, Apostolski S, Evoli A et al (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893–902PubMed
145.
Zurück zum Zitat Hohenstein B, Passauer J, Ziemssen T, Julius U (2015) Immunoadsorption with regenerating systems in neurological disorders – a single center experience. Atheroscler Suppl 18:119–123PubMed Hohenstein B, Passauer J, Ziemssen T, Julius U (2015) Immunoadsorption with regenerating systems in neurological disorders – a single center experience. Atheroscler Suppl 18:119–123PubMed
146.
Zurück zum Zitat Baggi F, Ubiali F, Nava S et al (2008) Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients. J Neuroimmunol 201–202:104–110PubMed Baggi F, Ubiali F, Nava S et al (2008) Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients. J Neuroimmunol 201–202:104–110PubMed
147.
Zurück zum Zitat Bucka C, Köhler W, Hertel G et al (1993) Immunadsorption bei Myasthenia gravis. Wirkungsweise, immunologische Parameter und klinischer Verlauf. Aktuelle Neurol 20:207–213 Bucka C, Köhler W, Hertel G et al (1993) Immunadsorption bei Myasthenia gravis. Wirkungsweise, immunologische Parameter und klinischer Verlauf. Aktuelle Neurol 20:207–213
148.
Zurück zum Zitat Zeitler H, Ulrich-Merzenich G, Hoffmann L et al (2006) Long-term effects of a multimodal approach including immunoadsorption for the treatment of myasthenic crisis. Artif Organs 30:597–605PubMed Zeitler H, Ulrich-Merzenich G, Hoffmann L et al (2006) Long-term effects of a multimodal approach including immunoadsorption for the treatment of myasthenic crisis. Artif Organs 30:597–605PubMed
149.
Zurück zum Zitat Sanders D, Wolfe G, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis. Neurology 87:419–425PubMedPubMedCentral Sanders D, Wolfe G, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis. Neurology 87:419–425PubMedPubMedCentral
150.
Zurück zum Zitat Gold R, Hohlfeld R, Toyka KV (2008) Progress in the treatment of myasthenia gravis. Ther Adv Neurol Disord 1(2):36–51PubMedPubMedCentral Gold R, Hohlfeld R, Toyka KV (2008) Progress in the treatment of myasthenia gravis. Ther Adv Neurol Disord 1(2):36–51PubMedPubMedCentral
151.
Zurück zum Zitat Liew WK, Powell CA, Sloan SR et al (2014) Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol 71:575–580PubMed Liew WK, Powell CA, Sloan SR et al (2014) Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol 71:575–580PubMed
152.
Zurück zum Zitat Della Marina A, Tripp H, Lutz S, Schara U (2014) Juvenile myasthenia gravis: recommendations for diagnostic approaches and treatment. Neuropediatrics 45:75–83PubMed Della Marina A, Tripp H, Lutz S, Schara U (2014) Juvenile myasthenia gravis: recommendations for diagnostic approaches and treatment. Neuropediatrics 45:75–83PubMed
153.
Zurück zum Zitat Koessler J, Kobsar A, Kuhn S et al (2015) The effect of immunoadsorption with the immusorba TR-350 on coagulation compared to plasma exchange. Vox Sang 108:46–21PubMed Koessler J, Kobsar A, Kuhn S et al (2015) The effect of immunoadsorption with the immusorba TR-350 on coagulation compared to plasma exchange. Vox Sang 108:46–21PubMed
154.
Zurück zum Zitat Köhler W, Sieb J (2012) Myasthenia gravis. UNI-MED, Bremen Köhler W, Sieb J (2012) Myasthenia gravis. UNI-MED, Bremen
155.
Zurück zum Zitat Trikha I, Singh S, Goyal V et al (2007) Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis. J Neurol 254:989–995PubMed Trikha I, Singh S, Goyal V et al (2007) Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis. J Neurol 254:989–995PubMed
156.
Zurück zum Zitat Koller H, Kieseier BC, Jander S, Hartung HP (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352:1343–1356PubMed Koller H, Kieseier BC, Jander S, Hartung HP (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352:1343–1356PubMed
157.
Zurück zum Zitat Goodfellow JA, Willison HJ (2016) Guillain-Barre syndrome: a century of progress. Nat Rev Neurol 12:723–731PubMed Goodfellow JA, Willison HJ (2016) Guillain-Barre syndrome: a century of progress. Nat Rev Neurol 12:723–731PubMed
158.
Zurück zum Zitat Alter M (1990) The epidemiology of Guillain-Barre syndrome. Ann Neurol 27(Suppl):S7–S12PubMed Alter M (1990) The epidemiology of Guillain-Barre syndrome. Ann Neurol 27(Suppl):S7–S12PubMed
159.
Zurück zum Zitat Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R, The Piemonte and Valle d’Aosta Register for Guillain-Barre Syndrome (2003) Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology 60:1146–1150PubMed Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R, The Piemonte and Valle d’Aosta Register for Guillain-Barre Syndrome (2003) Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology 60:1146–1150PubMed
161.
Zurück zum Zitat Chad DA, Hammer K, Sargent J (1986) Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology 36:1260–1263PubMed Chad DA, Hammer K, Sargent J (1986) Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology 36:1260–1263PubMed
162.
Zurück zum Zitat Roth G, Rohr J, Magistris MR, Ochsner F (1986) Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. Eur Neurol 25:416–423PubMed Roth G, Rohr J, Magistris MR, Ochsner F (1986) Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. Eur Neurol 25:416–423PubMed
163.
Zurück zum Zitat PNS-Task-Force (2010) Joint Task Force of the EFNS and the PNS: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. J Peripher Nerv Syst 15:295–301 PNS-Task-Force (2010) Joint Task Force of the EFNS and the PNS: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. J Peripher Nerv Syst 15:295–301
164.
Zurück zum Zitat Sommer C et al (2018) Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden, S2eLeitlinie. In: Deutsche Gesellschaft für Neurologie (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie (www.dgn.org/leitlinien abgerufen am 05.09.2018) Sommer C et al (2018) Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden, S2eLeitlinie. In: Deutsche Gesellschaft für Neurologie (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie (www.​dgn.​org/​leitlinien abgerufen am 05.09.2018)
165.
Zurück zum Zitat Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, Fazio R, Jann S, Mata S, Mazzeo A, Sabatelli M, Nobile-Orazio E, The Italian Network for CIDP Register (2010) A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 17:28994 Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, Fazio R, Jann S, Mata S, Mazzeo A, Sabatelli M, Nobile-Orazio E, The Italian Network for CIDP Register (2010) A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 17:28994
167.
Zurück zum Zitat Lopate G, Pestronk A, Al-Lozi M (2005) Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 62:249–254PubMed Lopate G, Pestronk A, Al-Lozi M (2005) Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 62:249–254PubMed
168.
Zurück zum Zitat Muley SA, Kelkar P, Parry GJ (2008) Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 65:1460–1464PubMed Muley SA, Kelkar P, Parry GJ (2008) Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 65:1460–1464PubMed
169.
Zurück zum Zitat van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JC, Vogels OJ, Hadden RD, Kleine BU, van Norden AG, Verschuuren JJ, Dijkgraaf MG, Vermeulen M (2010) Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 9:245–253PubMed van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JC, Vogels OJ, Hadden RD, Kleine BU, van Norden AG, Verschuuren JJ, Dijkgraaf MG, Vermeulen M (2010) Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 9:245–253PubMed
171.
Zurück zum Zitat Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, I. C. E. Study Group (2008) Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebocontrolled trial. Lancet Neurol 7:136–144PubMed Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, I. C. E. Study Group (2008) Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebocontrolled trial. Lancet Neurol 7:136–144PubMed
172.
Zurück zum Zitat Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Macchia R, Cavaletti G, Giannini F, Sabatelli M, I. M. C. Trial Group (2012) Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 11:493–502PubMed Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Macchia R, Cavaletti G, Giannini F, Sabatelli M, I. M. C. Trial Group (2012) Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 11:493–502PubMed
173.
Zurück zum Zitat Nobile-Orazio E, Cocito D, Jann S, Uncini A, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Cavaletti G, Giannini F, Sabatelli M, Beghi E, I. M. C. Trial Group (2015) Frequency and time to relapse after discontinuing 6‑month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry 86:729–734PubMed Nobile-Orazio E, Cocito D, Jann S, Uncini A, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Cavaletti G, Giannini F, Sabatelli M, Beghi E, I. M. C. Trial Group (2015) Frequency and time to relapse after discontinuing 6‑month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry 86:729–734PubMed
174.
Zurück zum Zitat Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC (2006) Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 63:1066–1071PubMed Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC (2006) Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 63:1066–1071PubMed
176.
Zurück zum Zitat Gold R, Stangel M, Dalakas MC (2007) Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3:36–44PubMed Gold R, Stangel M, Dalakas MC (2007) Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3:36–44PubMed
178.
Zurück zum Zitat Gorson KC, Ropper AH, Weinberg DH, Weinstein R (2002) Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59:766–772PubMed Gorson KC, Ropper AH, Weinberg DH, Weinstein R (2002) Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59:766–772PubMed
180.
Zurück zum Zitat Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. J Peripher Nerv Syst 15:185–195 Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. J Peripher Nerv Syst 15:185–195
181.
Zurück zum Zitat Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B (2009) Placebocontrolled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65:286–293PubMed Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B (2009) Placebocontrolled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65:286–293PubMed
182.
Zurück zum Zitat Leger JM, Viala K, Nicolas G, Creange A, Vallat JM, Pouget J, Clavelou P, Vial C, Steck A, Musset L, Marin B, Rimag Study Group (2013) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80:2217–2225PubMedPubMedCentral Leger JM, Viala K, Nicolas G, Creange A, Vallat JM, Pouget J, Clavelou P, Vial C, Steck A, Musset L, Marin B, Rimag Study Group (2013) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80:2217–2225PubMedPubMedCentral
183.
Zurück zum Zitat Hummel HD, Rath JC, Wiendl H, Hetzel W, Bargou RC, Toyka KV, Sommer C, Einsele H, Topp MS (2011) Auto-SCT in severe paraproteinemic neuropathy. Bone Marrow Transplant 46:457–459PubMed Hummel HD, Rath JC, Wiendl H, Hetzel W, Bargou RC, Toyka KV, Sommer C, Einsele H, Topp MS (2011) Auto-SCT in severe paraproteinemic neuropathy. Bone Marrow Transplant 46:457–459PubMed
184.
Zurück zum Zitat Lee YC, Came N, Schwarer A, Day B (2002) Autologous peripheral blood stem cell transplantation for peripheral neuropathy secondary to monoclonal gammopathy of unknown significance. Bone Marrow Transplant 30:53–56PubMed Lee YC, Came N, Schwarer A, Day B (2002) Autologous peripheral blood stem cell transplantation for peripheral neuropathy secondary to monoclonal gammopathy of unknown significance. Bone Marrow Transplant 30:53–56PubMed
186.
Zurück zum Zitat Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, Swanson C (1986) Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314:461–465PubMed Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, Swanson C (1986) Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314:461–465PubMed
187.
Zurück zum Zitat Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE (1996) Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119(Pt 4):1055–1066PubMed Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE (1996) Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119(Pt 4):1055–1066PubMed
188.
Zurück zum Zitat Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O’Brien PC (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845PubMed Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O’Brien PC (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845PubMed
189.
Zurück zum Zitat Choudhary PP, Hughes RA (1995) Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM 88:493–502PubMed Choudhary PP, Hughes RA (1995) Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM 88:493–502PubMed
190.
Zurück zum Zitat Pollard JD, McLeod JG, Gatenby P, Kronenberg H (1983) Prediction of response to plasma exchange in chronic relapsing polyneuropathy. A clinico-pathological correlation. J Neurol Sci 58:269–287PubMed Pollard JD, McLeod JG, Gatenby P, Kronenberg H (1983) Prediction of response to plasma exchange in chronic relapsing polyneuropathy. A clinico-pathological correlation. J Neurol Sci 58:269–287PubMed
192.
Zurück zum Zitat Galldiks N, Burghaus L, Dohmen C, Teschner S, Pollok M, Leebmann J, Frischmuth N, Hollinger P, Nazli N, Fassbender C, Klingel R, Benzing T, Fink GR, Haupt WF (2011) Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. Eur Neurol 66:183–189PubMed Galldiks N, Burghaus L, Dohmen C, Teschner S, Pollok M, Leebmann J, Frischmuth N, Hollinger P, Nazli N, Fassbender C, Klingel R, Benzing T, Fink GR, Haupt WF (2011) Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. Eur Neurol 66:183–189PubMed
193.
Zurück zum Zitat Raphael JC (1997) Appropriate number of plasma exchanges in Guillain-Barre syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol 41:298–306 Raphael JC (1997) Appropriate number of plasma exchanges in Guillain-Barre syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol 41:298–306
194.
Zurück zum Zitat Abd-Allah SA, Jansen PW, Ashwal S, Perkin RM (1997) Intravenous immunoglobulin as therapy for pediatric Guillain-Barre syndrome. J Child Neurol 12:376–380PubMed Abd-Allah SA, Jansen PW, Ashwal S, Perkin RM (1997) Intravenous immunoglobulin as therapy for pediatric Guillain-Barre syndrome. J Child Neurol 12:376–380PubMed
195.
196.
Zurück zum Zitat Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K (1996) Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology 46:100–103PubMed Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K (1996) Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology 46:100–103PubMed
197.
Zurück zum Zitat Donofrio PD (2003) Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve 28:273–292PubMed Donofrio PD (2003) Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve 28:273–292PubMed
198.
Zurück zum Zitat Epstein MA, Sladky JT (1990) The role of plasmapheresis in childhood Guillain-Barre syndrome. Ann Neurol 28:65–69PubMed Epstein MA, Sladky JT (1990) The role of plasmapheresis in childhood Guillain-Barre syndrome. Ann Neurol 28:65–69PubMed
199.
Zurück zum Zitat Esperou H, Jars-Guincestre MC, Bolgert F, Raphael JC, Durand-Zaleski I (2000) Cost analysis of plasmaexchange therapy for the treatment of Guillain-Barre syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Intensive Care Med 26:1094–1100PubMed Esperou H, Jars-Guincestre MC, Bolgert F, Raphael JC, Durand-Zaleski I (2000) Cost analysis of plasmaexchange therapy for the treatment of Guillain-Barre syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Intensive Care Med 26:1094–1100PubMed
200.
Zurück zum Zitat Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC, The Quality Standards Subcommittee of the American Academy of Neurology (2003) Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 61:736–740PubMed Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC, The Quality Standards Subcommittee of the American Academy of Neurology (2003) Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 61:736–740PubMed
201.
Zurück zum Zitat Jansen PW, Perkin RM, Ashwal S (1993) Guillain-Barre syndrome in childhood: natural course and efficacy of plasmapheresis. Pediatr Neurol 9:16–20PubMed Jansen PW, Perkin RM, Ashwal S (1993) Guillain-Barre syndrome in childhood: natural course and efficacy of plasmapheresis. Pediatr Neurol 9:16–20PubMed
202.
Zurück zum Zitat Jones HR (1996) Childhood Guillain-Barre syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol 11:4–12PubMed Jones HR (1996) Childhood Guillain-Barre syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol 11:4–12PubMed
203.
Zurück zum Zitat McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA (1988) Plasmapheresis and Guillain-Barre syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 23:347–353PubMed McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA (1988) Plasmapheresis and Guillain-Barre syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 23:347–353PubMed
204.
Zurück zum Zitat Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Siden A, Safwenberg J (1984) Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 2:1296–1299PubMed Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Siden A, Safwenberg J (1984) Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 2:1296–1299PubMed
205.
Zurück zum Zitat Vallee L, Dulac O, Nuyts JP, Leclerc F, Vamecq J (1993) Intravenous immune globulin is also an efficient therapy of acute Guillain-Barre syndrome in affected children. Neuropediatrics 24:235–236PubMed Vallee L, Dulac O, Nuyts JP, Leclerc F, Vamecq J (1993) Intravenous immune globulin is also an efficient therapy of acute Guillain-Barre syndrome in affected children. Neuropediatrics 24:235–236PubMed
206.
Zurück zum Zitat Yuki N, Tagawa Y, Hirata K (1998) Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barre syndrome. Neurology 51:875–877PubMed Yuki N, Tagawa Y, Hirata K (1998) Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barre syndrome. Neurology 51:875–877PubMed
207.
Zurück zum Zitat McKhann GM (1985) Plasmapheresis and acute Guillain-Barre syndrome. The Guillain-Barre syndrome Study Group. Neurology 35:1096–1104 McKhann GM (1985) Plasmapheresis and acute Guillain-Barre syndrome. The Guillain-Barre syndrome Study Group. Neurology 35:1096–1104
208.
Zurück zum Zitat van der Meche FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326:1123–1129PubMed van der Meche FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326:1123–1129PubMed
209.
Zurück zum Zitat PSGBS-Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet 349:225–230 PSGBS-Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet 349:225–230
210.
Zurück zum Zitat Diener HC, Haupt WF, Kloss TM, Rosenow F, Philipp T, Koeppen S, Vietorisz A, Group Study (2001) A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barre syndrome. Eur Neurol 46:107–109PubMed Diener HC, Haupt WF, Kloss TM, Rosenow F, Philipp T, Koeppen S, Vietorisz A, Group Study (2001) A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barre syndrome. Eur Neurol 46:107–109PubMed
211.
Zurück zum Zitat El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM (2011) Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barre syndrome: a randomized study. Crit Care 15:R164PubMedPubMedCentral El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM (2011) Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barre syndrome: a randomized study. Crit Care 15:R164PubMedPubMedCentral
212.
Zurück zum Zitat Gurses N, Uysal S, Cetinkaya F, Islek I, Kalayci AG (1995) Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Scand J Infect Dis 27:241–243PubMed Gurses N, Uysal S, Cetinkaya F, Islek I, Kalayci AG (1995) Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Scand J Infect Dis 27:241–243PubMed
213.
Zurück zum Zitat Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G (1997) Sequential treatment of Guillain-Barre syndrome with extracorporeal elimination and intravenous immunoglobulin. Ther Apher 1:55–57PubMed Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G (1997) Sequential treatment of Guillain-Barre syndrome with extracorporeal elimination and intravenous immunoglobulin. Ther Apher 1:55–57PubMed
214.
Zurück zum Zitat Korinthenberg R, Schessl J, Kirschner J, Monting JS (2005) Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatr Electron Pages 116:8–14 Korinthenberg R, Schessl J, Kirschner J, Monting JS (2005) Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatr Electron Pages 116:8–14
215.
Zurück zum Zitat Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC, French Guillain-Barre Syndrome Cooperative Group (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235–238PubMedPubMedCentral Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC, French Guillain-Barre Syndrome Cooperative Group (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235–238PubMedPubMedCentral
216.
Zurück zum Zitat Galldiks N, Dohmen C, Neveling M, Fink GR, Haupt WF (2009) Selective immune adsorption treatment of severe Guillain Barre syndrome in the intensive care unit. Neurocrit Care 11:317–321PubMed Galldiks N, Dohmen C, Neveling M, Fink GR, Haupt WF (2009) Selective immune adsorption treatment of severe Guillain Barre syndrome in the intensive care unit. Neurocrit Care 11:317–321PubMed
217.
Zurück zum Zitat Marn Pernat A, Buturovic-Ponikvar J, Svigelj V, Ponikvar R (2009) Guillain-Barre syndrome treated by membrane plasma exchange and/or immunoadsorption. Ther Apher Dial 13:310–313PubMed Marn Pernat A, Buturovic-Ponikvar J, Svigelj V, Ponikvar R (2009) Guillain-Barre syndrome treated by membrane plasma exchange and/or immunoadsorption. Ther Apher Dial 13:310–313PubMed
218.
Zurück zum Zitat Seta T, Nagayama H, Katsura K, Hamamoto M, Araki T, Yokochi M, Utsumi K, Katayama Y (2005) Factors influencing outcome in Guillain-Barre syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg 107:491–496PubMed Seta T, Nagayama H, Katsura K, Hamamoto M, Araki T, Yokochi M, Utsumi K, Katayama Y (2005) Factors influencing outcome in Guillain-Barre syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg 107:491–496PubMed
219.
Zurück zum Zitat Okamiya S, Ogino M, Ogino Y, Irie S, Kanazawa N, Saito T, Sakai F (2004) Tryptophan-immobilized columnbased immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome. Ther Apher Dial 8:248253 Okamiya S, Ogino M, Ogino Y, Irie S, Kanazawa N, Saito T, Sakai F (2004) Tryptophan-immobilized columnbased immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome. Ther Apher Dial 8:248253
220.
Zurück zum Zitat Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, Smith BE, Kratz KM, Karnes JL, Evans BA et al (1991) Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 325:1482–1486PubMed Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, Smith BE, Kratz KM, Karnes JL, Evans BA et al (1991) Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 325:1482–1486PubMed
222.
Zurück zum Zitat Raphael JC (1987) Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol 22:753–761 Raphael JC (1987) Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol 22:753–761
223.
Zurück zum Zitat Raphael JC (1992) Plasma exchange in Guillain-Barre syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol 32:94–97 Raphael JC (1992) Plasma exchange in Guillain-Barre syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol 32:94–97
Metadaten
Titel
Konsensuspapier zum Einsatz der therapeutischen Apherese in der Neurologie
verfasst von
W. Köhler
C. G. Bien
S. Ehrlich
J. Faiss
C. Finke
R. Gold
A. Günther
L. Harms
F. Heigl
J. Heine
F. Hoffmann
R. W. C. Janzen
G. J. Jungehülsing
B. Kieseier
I. Kleiter
A. Kraft
F. Paul
H. Prüß
S. Schimrigk
C. Sommer
M. Stettner
C. Trebst
H. Tumani
Publikationsdatum
11.01.2019
Verlag
Springer Medizin
Erschienen in
DGNeurologie / Ausgabe 1/2019
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI
https://doi.org/10.1007/s42451-018-0051-1

Weitere Artikel der Ausgabe 1/2019

DGNeurologie 1/2019 Zur Ausgabe

Eine Frage des Rechts

Alter Wein in neuen Schläuchen

Magazin

Magazin

Passend zum Thema

ANZEIGE
OnSite Advertorial Multiple Sklerose
Service mit Mehrwert

Services in der MS-Therapie für Neurolog*innen und Betroffene

Diagnose und Therapie der MS können für Patient*innen und Neurolog*innen mit Herausforderungen einhergehen [1,2]. Mit umfangreichen Servicemaßnahmen klärt Biogen Ärztinnen und Ärzte über mögliche Therapieoptionen auf und unterstützt diese bei der Fortbildung sowie Betroffene im Alltag.